• Original tranche of $25 million supplies funding in preparing for registrational demo for guide candidate PDS0101

• Convention simply call scheduled for Thursday, August 25, 2022 at 8:00 AM EDT

FLORHAM PARK, N.J., Aug. 24, 2022 (World NEWSWIRE) — PDS Biotechnology Company (Nasdaq: PDSB), a medical-stage immunotherapy organization building a increasing pipeline of molecularly focused cancer immunotherapies and infectious illness vaccines dependent on the Company’s proprietary Versamune^® and Infectimune™ T mobile activating systems, now declared that it has entered into a personal debt financing agreement led by Horizon Technological innovation Finance Corporation (NASDAQ: HRZN) (“Horizon”) to offer up to a $35. million time period bank loan.

“We are happy to associate with Horizon, a foremost specialty finance company that has an considerable historical past of supporting impressive lifestyle science providers,” claimed Frank Bedu-Addo, Main Executive Officer of PDS Biotech. “We anticipate a range of critical milestones throughout our oncology and infectious disorder courses. This transaction straight away strengthens our harmony sheet and presents the money methods required to advance the company’s medical pipeline.  We glance ahead to our assembly with the U.S. Food items and Drug Administration this quarter to go over the registrational trial style and design for our lead method.”

As aspect of the financing, PDS Biotech obtained an original tranche of $25 million at the shut. The Enterprise has an option to receive an supplemental $10 million. Each individual progress of the loan will be repaid in 48 month-to-month payments consisting of 24 monthly payments of fascination only, adopted by 24 regular payments of principal and accrued desire. In connection with the funding, PDS Biotech issued Horizon warrants to acquire up to 4% of the personal loan amount of money, 381,625 of its frequent shares at an workout rate of $3.6685 for every share. Proceeds will be made use of to aid the ongoing clinical improvement of PDS0101 and other solution candidates inside of the company’s pipeline and for standard working cash uses.

Tale carries on

Further data with respect to the credit card debt financing settlement with Horizon will be contained in a recent report to be filed on Kind 8-K by PDS Biotechnology with the Securities and Exchange Fee.

Meeting Phone and Webcast
The meeting phone is scheduled for Thursday, August 25, 2022 at 8:00 AM EDT. Participants need to dial 877-407-3088 (United States) or 201-389-0927 (Intercontinental) and reference convention ID 13732262. To access the webcast, make sure you use the next hyperlink. The celebration will be archived in the trader relations part of PDS Biotech’s web-site for 6 months.

About PDS Biotechnology
PDS Biotech is a clinical-phase immunotherapy firm developing a rising pipeline of qualified cancer and infectious disorder immunotherapies primarily based on our proprietary Versamune^® and Infectimune™ T cell-activating technology platforms. We believe that our specific Versamune^® dependent candidates have the opportunity to get over the limitations of present immunotherapy by inducing massive portions of substantial-top quality, hugely powerful polyfunctional tumor certain CD4+ helper and CD8+ killer T cells. To date, our guide Versamune^® clinical applicant, PDS0101, has demonstrated the means to decrease tumors and stabilize disorder in mixture with permitted and investigational therapeutics in individuals with a wide selection of HPV16-associated cancers in many Stage 2 clinical trials. Our Infectimune™ dependent vaccines have also demonstrated the probable to induce not only robust and sturdy neutralizing antibody responses, but also potent T cell responses, including long-long lasting memory T cell responses in pre-scientific scientific studies to date. To discover much more, please check out www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About Horizon Know-how Finance
Horizon Technology Finance Company (NASDAQ: HRZN) is a major specialty finance enterprise that offers money in the form of secured financial loans to enterprise capital backed corporations in the engineering, existence science, healthcare facts and companies, and sustainability industries. The investment objective of Horizon is to maximize its expenditure portfolio’s return by creating current cash flow from the credit card debt investments it would make and capital appreciation from the warrants it gets when earning these kinds of personal debt investments. Horizon is headquartered in Farmington, Connecticut, with a regional business office in Pleasanton, California, and expenditure specialists found in Portland, Maine, Austin, Texas, and Reston, Virginia. To master additional, please go to www.horizontechfinance.com.

Forward Looking Statements
This conversation has forward-seeking statements (which include inside the this means of Area 21E of the United States Securities Trade Act of 1934, as amended, and Portion 27A of the United States Securities Act of 1933, as amended) regarding PDS Biotechnology Company (the “Company”) and other issues. These statements may well examine targets, intentions and anticipations as to foreseeable future designs, trends, gatherings, success of operations or fiscal issue, or normally, primarily based on latest beliefs of the Company’s management, as perfectly as assumptions manufactured by, and information and facts now readily available to, management. Forward-looking statements frequently include statements that are predictive in nature and depend upon or refer to future situations or circumstances, and involve words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other very similar expressions among others. Ahead-searching statements are primarily based on recent beliefs and assumptions that are topic to challenges and uncertainties and are not guarantees of upcoming efficiency. Genuine outcomes could vary materially from individuals contained in any ahead-searching statement as a consequence of a variety of elements, including, without having limitation: the Company’s capacity to guard its mental house rights the Company’s predicted capital needs, which includes the Company’s expected dollars runway and the Company’s recent anticipations relating to its plans for upcoming equity financings the Company’s dependence on extra financing to fund its operations and full the advancement and commercialization of its solution candidates, and the hazards that increasing such supplemental money may possibly restrict the Company’s operations or have to have the Company to relinquish legal rights to the Company’s technologies or solution candidates the Company’s constrained running historical past in the Company’s present line of business, which can make it complicated to examine the Company’s prospective clients, the Company’s company strategy or the chance of the Company’s effective implementation of this kind of enterprise plan the timing for the Enterprise or its associates to initiate the prepared medical trials for PDS0101, PDS0203 and other Versamune^® and Infectimune™ centered solution candidates the potential achievements of this sort of trials the prosperous implementation of the Company’s research and enhancement programs and collaborations, like any collaboration research about PDS0101, PDS0203 and other Versamune^® and Infectimune™ based products candidates and the Company’s interpretation of the final results and findings of these kinds of courses and collaborations and irrespective of whether these types of outcomes are adequate to aid the foreseeable future results of the Company’s products candidates the achievements, timing and price of the Company’s ongoing scientific trials and anticipated scientific trials for the Company’s recent item candidates, together with statements concerning the timing of initiation, speed of enrollment and completion of the trials (together with the Company’s capacity to entirely fund its disclosed scientific trials, which assumes no content changes to our currently projected expenditures), futility analyses, displays at conferences and information documented in an summary, and receipt of interim or preliminary benefits (such as, without limitation, any preclinical success or info), which are not necessarily indicative of the remaining results of the Company’s ongoing scientific trials any Business statements about its knowledge of solution candidates mechanisms of motion and interpretation of preclinical and early clinical results from its scientific enhancement systems and any collaboration scientific tests and other aspects, like legislative, regulatory, political and economic developments not inside the Company’s manage, which includes record inflation, unexpected circumstances or other disruptions to normal company functions arising from or relevant to COVID-19 and the ongoing armed service conflict concerning Russia and Ukraine. The foregoing review of essential things that could bring about real gatherings to differ from anticipations should not be construed as exhaustive and should really be examine in conjunction with statements that are included herein and somewhere else, like the chance things integrated in the Company’s yearly and periodic experiences submitted with the SEC. The ahead-searching statements are built only as of the date of this press release and, except as demanded by relevant law, the Company undertakes no obligation to revise or update any forward-hunting statement, or to make any other ahead-on the lookout statements, whether or not as a result of new information, future functions or in any other case.

Versamune^® is a registered trademark and Infectimune™ is a trademark of PDS Biotechnology.

Trader Contacts:
Deanne Randolph
PDS Biotech
Mobile phone: +1 (908) 517-3613
E-mail: [email protected]

Nicole Jones
CG Cash
Cellular phone: +1 (404) 736-3838
E mail: [email protected]